Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial.
Susan M BuenoKatia AbarcaPablo A GonzálezNicolás M S GálvezJorge A SotoLuisa F DuarteBárbara M SchultzGaspar A PachecoLiliana A GonzálezYaneisi VázquezMariana RíosFelipe Melo-GonzálezDaniela Rivera-PérezCarolina IturriagaMarcela UrzúaAngélica DominguezCatalina A AndradeRoslye V BerriosGisela Canedo-MarroquínCamila CoviánDaniela Moreno-TapiaFarides SaavedraOmar P VallejosPaulina DonatoPilar EspinozaDaniela FuentesMarcela GonzálezPaula GuzmánPaula Muñoz-VenturelliCarlos M PérezMarcela PotinAlvaro RojasRodrigo FasceJorge FernándezJudith MoraEugenio RamírezAracelly Gaete-ArgelAarón Oyarzún-ArrauFernando Valiente-EcheverríaRicardo Soto-RifoDaniela WeiskopfAlessandro SetteGang ZengWeining MengJosé V González-AramundizAlexis M KalergisPublished in: medRxiv : the preprint server for health sciences (2021)
Ministry of Health of the Chilean Government; Confederation of Production and Commerce, Chile; Consortium of Universities for Vaccines and Therapies against COVID-19, Chile; Millennium Institute on Immunology and Immunotherapy.